Motley Fool : INCY Provides Incredibly Good News. POST.
Motley Fool 8/23/13 By: Sean Williams
As you can tell by today's move higher, this is incredibly good early stage news for advanced metastatic pancreatic sufferers. Furthermore, it appears that Incyte has already honed in on which subgroups would benefit most by JAK pathway inhibition, meaning that a companion diagnostic test may be unnecessary. Jakafi delivered improved overall survivial in a phase 3 myelofibrosis trial, which lends hope that ruxolitinibto treat metastatic prostate cancer will do the same.